01.28.25 -- 5 Characteristics Of Forward-Thinking Microbiology Labs In 2025

The antibody-drug conjugate manufacturing supply chain contains five different technologies with specific asset needs: monoclonal antibody, cytotoxic payload, linker, bioconjugation, and fill and finish.

In addition to codifying some best practices, R3 recommends that sponsors adopt an approach to identifying and managing areas of risk to mitigate potential issues and enhance overall success.

Discover how companies can de-risk their device selection as they bring this new generation of high-volume, high-viscosity biologics to market.

Avoid FDA recalls and safeguard your life sciences business. Learn how QMS and EBR/eDHR solutions can prevent costly product recalls and ensure compliance with FDA regulations.

Standardization and flexibility in aseptic filling were thought to be mutually exclusive. But what if there was a standardized system with flexibility built into the aseptic process, so you didn’t have to choose?

Examine how revolutionary and environmentally sustainable nanoparticle technologies coupled with innovative formulation approaches can address drug solubility issues and add value for patients.

Explore how the FDA's Real-World Evidence framework helps integrate real-world data into drug approval, improving efficiency, while ensuring data reliability and regulatory compliance.

Discover a solution that ensures particularly efficient and reliable vertical and horizontal form fill and seal machine labeling.

Watch to learn how to optimize GLP-1 production, how throughput and performance affect downstream processes in protein therapies, and how to enhance yield and purity for optimal process outcomes.

Explore the processes and technologies being utilized by life sciences manufacturers to achieve success on their Industrial DataOps maturity journey as well as real-world best practices from the field.

GMP compliance requires monitoring microbial contamination levels in cleanrooms and clean spaces. It is important to know the role active air samplers play in this process and parameters for evaluating them.

Examine how 780 human Liver-Chips were assessed for their ability to predict drug-induced liver injury from small molecules.

Highly potent materials bring additional challenges to manufacturing processes. Examine considerations for optimizing HPAPI production methods to reduce risk and deliver therapies to patients with speed.